187 related articles for article (PubMed ID: 30312577)
1. Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study.
Dana R; Bradley JL; Guerin A; Pivneva I; Evans AM; Stillman IÖ
Am J Ophthalmol; 2019 Feb; 198():181-192. PubMed ID: 30312577
[TBL] [Abstract][Full Text] [Related]
2. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System.
Dana R; Bradley JL; Guerin A; Pivneva I; Stillman IÖ; Evans AM; Schaumberg DA
Am J Ophthalmol; 2019 Jun; 202():47-54. PubMed ID: 30721689
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Determinants of Dry Eye Disease among 40 Years and Older Population of Riyadh (Except Capital), Saudi Arabia.
Yasir ZH; Chauhan D; Khandekar R; Souru C; Varghese S
Middle East Afr J Ophthalmol; 2019; 26(1):27-32. PubMed ID: 31114121
[TBL] [Abstract][Full Text] [Related]
4. Burden of dry eye disease in Germany: a retrospective observational study using German claims data.
Siffel C; Hennies N; Joseph C; Lascano V; Horvat P; Scheider M; Ganzera F
Acta Ophthalmol; 2020 Jun; 98(4):e504-e512. PubMed ID: 31736282
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of co-morbid eye disease in patients with chronic renal failure: a population-based study.
Wang TJ; Wu CK; Hu CC; Keller JJ; Lin HC
Ophthalmic Epidemiol; 2012 Jun; 19(3):137-43. PubMed ID: 22568426
[TBL] [Abstract][Full Text] [Related]
6. Association between Glaucoma Medication Usage and Dry Eye in Taiwan.
Chen HY; Lin CL; Tsai YY; Kao CH
Optom Vis Sci; 2015 Sep; 92(9):e227-32. PubMed ID: 26192153
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
[TBL] [Abstract][Full Text] [Related]
8. Dry eye disease ranking among common reasons for seeking eye care in a large US claims database.
Bradley JL; Özer Stillman I; Pivneva I; Guerin A; Evans AM; Dana R
Clin Ophthalmol; 2019; 13():225-232. PubMed ID: 30774303
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine Anionic and Cationic Ophthalmic Emulsions in Dry Eye Disease: A Literature Review.
Tong L; Sun CC; Yoon KC; Lim Bon Siong R; Puangsricharern V; Baudouin C
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1606-1615. PubMed ID: 32469256
[No Abstract] [Full Text] [Related]
10. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.
Sacchetti M; Mantelli F; Lambiase A; Mastropasqua A; Merlo D; Bonini S
Br J Ophthalmol; 2014 Aug; 98(8):1016-22. PubMed ID: 24344232
[TBL] [Abstract][Full Text] [Related]
12. Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care.
Chiang TH; Walt JG; McMahon JP; Mansfield JE; Simonyi S
Can J Clin Pharmacol; 2007; 14(2):e240-5. PubMed ID: 17622671
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children.
Hoehn ME; Kelly SR; Wilson MW; Walton RC
Pediatr Blood Cancer; 2013 Jul; 60(7):E35-7. PubMed ID: 23335290
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical characteristics of dry eye disease in community-based type 2 diabetic patients: the Beixinjing eye study.
Zou X; Lu L; Xu Y; Zhu J; He J; Zhang B; Zou H
BMC Ophthalmol; 2018 May; 18(1):117. PubMed ID: 29747621
[TBL] [Abstract][Full Text] [Related]
15. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
Leonardi A; Flamion B; Baudouin C
Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
[TBL] [Abstract][Full Text] [Related]
16. [The place of ciclosporin A cationic emulsion 0.1% in the therapy of xerophthalmia].
Maychuk DY; Yani EV; Brzheskiy VV; Grishina EE; Drozdova EA; Maychuk NV; Panova IE; Safonova TN
Vestn Oftalmol; 2024; 140(2):102-111. PubMed ID: 38742506
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older.
Farrand KF; Fridman M; Stillman IÖ; Schaumberg DA
Am J Ophthalmol; 2017 Oct; 182():90-98. PubMed ID: 28705660
[TBL] [Abstract][Full Text] [Related]
18. Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus.
Yao YP; Yang PJ; Lee CY; Huang JY; Yang SF; Lin HY
Int J Med Sci; 2023; 20(13):1705-1710. PubMed ID: 37928879
[TBL] [Abstract][Full Text] [Related]
19. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
Nichols KK; Evans DG; Karpecki PM
Curr Eye Res; 2021 May; 46(5):609-614. PubMed ID: 33238774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
